stockrow
Friday 6 November 2026
Export CSTL’s income statement to Excel — free account
Castle Biosciences, Inc.
CSTL Healthcare Diagnostics & Research
Castle Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $344.2 million, up 3.66% from fiscal 2024.
- Revenue
- +23.9%
- EPS
- −550.0%
- Free cash flow
- +56.8%
- Total debt
- −59.9%
Quarter to September 2026, against a year earlier
32.43
1.77
−5.18%
Follow CSTL
Alert me
Castle Biosciences, Inc. (CSTL) P/E ratio
Castle Biosciences, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 165× (October 2024) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 41.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Sep 2026 | 0.0× | — |
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| 29 more quarters | Free account |
Against its own ten years
Low 0.0×
High 165×
Ten-year median
0.0×
Current reading's percentile
90
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| WGS GeneDx Holdings Corp. compare | n/m |
| CSTL Castle Biosciences, Inc. | n/m |
| NEO NeoGenomics, Inc. compare | n/m |
| MYGN Myriad Genetics, Inc. compare | n/m |
| FLGT Fulgent Genetics, Inc. compare | n/m |
| OPK OPKO Health, Inc. compare | n/m |
| FRNM Freenome, Inc compare | n/m |
| PSNL Personalis, Inc. compare | n/m |
| VCYT Veracyte, Inc. compare | 15.2× |
| Diagnostics & Research industry median | 34.5× |
| Healthcare sector median | 25.2× |
| Market median | 17.9× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)